New pill aims to supercharge radiation against tough cancers
NCT ID NCT02381561
Summary
This early-stage study is testing a new oral drug called ropidoxuridine (IPdR) in patients with advanced gastrointestinal cancers that have spread. The main goal is to find the safest dose of the drug when taken daily alongside standard radiation therapy. Researchers hope the drug will make cancer cells more sensitive to radiation, potentially improving treatment for these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Conditions
Explore the condition pages connected to this study.